Want to see PEPG full AI Analyst Report?
PEPG Stock Chart & Stats
$1.93
-$0.17(-8.10%)
At close: 4:00 PM EDT
$1.93
-$0.17(-8.10%)
Day’s Range― - ―
52-Week Range$1.13 - $7.80
Previous CloseN/A
Volume735.00K
Average Volume (3M)6.68M
Market Cap
$217.47M
Enterprise Value$23.42
Total Cash (Recent Filing)$117.24M
Total Debt (Recent Filing)$16.09M
Price to Earnings (P/E)―
Beta0.88
Next Earnings
Mar 10, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.50
Shares Outstanding69,259,514
10 Day Avg. Volume930,736
30 Day Avg. Volume6,679,177
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)1.86
Price to Sales (P/S)0.00
P/FCF Ratio-3.36
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$10.50Price Target Upside444.04% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.06
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Pipeline AdvancementProgression into higher-dose cohorts and planned regulatory engagement indicate the lead program is advancing through clinical development. This could improve the platform’s long-term value if upcoming data support efficacy and safety.
Substantial Cash RunwayThe reported cash and marketable securities balance supports operations into the fourth quarter of 2027. This gives PepGen time to generate clinical data and pursue development milestones before financing pressure becomes more immediate.
Manageable LeverageLow leverage limits fixed financial obligations relative to the equity base, an important advantage for a clinical-stage biotech. It preserves flexibility to allocate capital toward research and trials rather than substantial debt service.
Bears Say
No Commercial RevenuePepGen has no approved commercial products and no demonstrated revenue stream, so its business model remains dependent on successful clinical development. Until a program reaches commercialization or partnership monetization, operating performance cannot self-fund growth.
Persistent Cash BurnSustained negative operating and free cash flow shows that PepGen is not self-funding its pipeline. Continued trial investment will likely require external capital over time, creating dilution or financing risk if development needs exceed available resources.
Ongoing Losses And Shrinking EquityLarge recurring losses remain far from breakeven and have reduced the capital base over time. This weakens financial resilience and increases dependence on future funding, particularly if clinical programs require longer or more costly development.
PepGen Inc. News
PEPG FAQ
What was PepGen Inc.’s price range in the past 12 months?
PepGen Inc. lowest stock price was $1.13 and its highest was $7.80 in the past 12 months.
What is PepGen Inc.’s market cap?
PepGen Inc.’s market cap is $217.47M.
When is PepGen Inc.’s upcoming earnings report date?
PepGen Inc.’s upcoming earnings report date is Mar 10, 2027 which is in 198 days.
How were PepGen Inc.’s earnings last quarter?
PepGen Inc. released its earnings results on Aug 06, 2026. The company reported -$0.26 earnings per share for the quarter, beating the consensus estimate of -$0.284 by $0.024.
Is PepGen Inc. overvalued?
According to Wall Street analysts PepGen Inc.’s price is currently Undervalued.
Does PepGen Inc. pay dividends?
PepGen Inc. does not currently pay dividends.
What is PepGen Inc.’s EPS estimate?
PepGen Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PepGen Inc. have?
PepGen Inc. has 69,259,514 shares outstanding.
What happened to PepGen Inc.’s price movement after its last earnings report?
PepGen Inc. reported an EPS of -$0.26 in its last earnings report, beating expectations of -$0.284. Following the earnings report the stock price went up 21.717%.
Which hedge fund is a major shareholder of PepGen Inc.?
Currently, no hedge funds are holding shares in PEPG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
PepGen Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.50 (444.04% Upside)
$10.50 (444.04% Upside)
Hedge Fund Trend
Decreased
By 1.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.0%
Last 30 Days ▼ 2.1%
Last 30 Days ▼ 2.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-44.87%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
38.30%
Trailing 12-Months
Company Description
PepGen Inc.
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.
PEPG Stock 12 Month Forecast
Average Price Target
$10.50
▲(444.04% Upside)
Technical Analysis
Rocket Pharmaceuticals
―
Editas Medicine
―
―
Lyell Immunopharma
―
Lexeo Therapeutics, Inc.
―
Ownership Overview
37.00% Insiders
3.69% Mutual Funds
4.85% Other Institutional Investors
50.48% Public Companies and
Individual Investors